多西环素与阿奇霉素治疗直肠衣原体感染疗效的系统评价与荟萃分析
该系统评价与荟萃分析比较多西环素与单剂阿奇霉素治疗直肠衣原体感染的疗效,纳入2项随机对照试验和9项观察性研究共2457例患者。结果显示多西环素微生物学治愈率显著高于阿奇霉素(RR=1.21,95%CI 1.15-1.28,P<0.05),推荐在发达国家将多西环素作为一线治疗。
要点
- 多西环素治疗直肠衣原体的微生物学治愈率高于阿奇霉素。
- 推荐在发达国家将多西环素作为直肠衣原体一线治疗。
- 仍需发展中国家开展更多随机对照试验验证。
核心结论
- 在发达国家,推荐多西环素而非阿奇霉素作为直肠衣原体感染的一线治疗。
研究设计与样本
- 系统评价与荟萃分析,检索PubMed、EMBASE、Cochrane Library、Web of Science和clinicaltrials.gov从建库至2021年7月7日。
- 纳入2项随机对照试验和9项观察性研究,共2457例患者,比较多西环素与单剂阿奇霉素的疗效。
- 所有纳入研究均在发达国家进行,采用随机效应模型合成数据并进行亚组分析。
主要发现
- 多西环素微生物学治愈率高于阿奇霉素(风险比=1.21;95%CI=1.15-1.28;P<0.05)。
- 两项随机对照试验的汇总结果同样显示多西环素治愈率更高(风险比=1.27;95%CI=1.20-1.35;P<0.05)。
- 在不同研究设计、国家和性别的亚组中结果保持一致。
关键数值与推荐
- 多西环素对比阿奇霉素的微生物学治愈率风险比=1.21(95%CI 1.15-1.28,P<0.05)。
- 随机对照试验亚组风险比=1.27(95%CI 1.20-1.35,P<0.05)。
临床怎么用
- 在发达国家临床实践中,可优先选用多西环素治疗直肠衣原体感染。
- 单剂阿奇霉素的治愈率较低,不宜作为首选方案。
局限性
- 所有纳入研究均来自发达国家,结论外推至发展中国家需谨慎。
- 纳入研究包含观察性研究,可能存在混杂偏倚。
- 需要更多来自发展中国家的随机对照试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chlamydia trachomatis infection is the most common sexually transmitted infectious disease and carries a risk of complications. However, the optimal treatment for rectal chlamydial infection remains unclear. OBJECTIVES: To compare the efficacy of doxycycline and azithromycin for the treatment of rectal chlamydia by undertaking a systematic review and meta-analysis of published data. METHODS: We searched PubMed, EMBASE, Cochrane Library, Web of Science and clinicaltrials.gov databases from inception to 7 July 2021 for randomized controlled trials (RCTs) and observational studies that compared the efficacy of doxycycline and single-dose azithromycin on rectal chlamydia cure rates. Data were synthesized using a random-effects model, and subgroup analysis was conducted. RESULTS: All included studies were conducted in developed countries. Two RCTs and nine observational studies, with a total of 2457 patients, were analysed. Doxycycline had a higher microbiological cure rate than azithromycin (risk ratio = 1.21; 95% CI = 1.15-1.28; P < 0.05). Pooled results from two RCTs also revealed a higher microbiological cure rate for doxycycline than azithromycin (risk ratio = 1.27; 95% CI = 1.20-1.35; P < 0.05). The results remained consistent in subgroups of different study designs, countries and sexes. CONCLUSIONS: On the basis of our findings, we recommend doxycycline rather than azithromycin as a first-line treatment for rectal chlamydia in developed countries. More RCTs from developing countries are warranted.
引用
- Chen LF, Wang TC, Chen FL, et al. Efficacy of doxycycline versus azithromycin for the treatment of rectal chlamydia: a systematic review and meta-analysis. J Antimicrob Chemother. 2021. PMID: 34529798. doi:10.1093/jac/dkab335
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。